Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.
about
Hepatitis C Virus and Liver Transplantation.Alcohol Consumption in Concomitant Liver Disease: How Much is Too Much?Same policy, different impact: Center-level effects of share 35 liver allocation.Impact of etiological treatment on prognosis.Impact of hepatitis C oral therapy in portal hypertension.Risk factors for biopsy-proven advanced non-alcoholic fatty liver disease in the Veterans Health Administration.Transplanting HCV-positive livers into HCV-negative patients with preemptive antiviral treatment: A modeling study.Advances and challenges in cirrhosis and portal hypertension.Non-Alcoholic Fatty Liver Disease: The Emerging Burden in Cardiometabolic and Renal Diseases.Clinical trials using mesenchymal stem cells in liver diseases and inflammatory bowel diseases.Hypergammaglobulinemia is a strong predictor of disease progression, hepatocellular carcinoma, and death in patients with compensated cirrhosis.Current and future pharmacological therapies for NAFLD/NASH.Fatty liver disease, an emerging etiology of hepatocellular carcinoma in Argentina.Recent trends in liver transplantation for alcoholic liver disease in the United States.Epigenetically mediated inhibition of S-adenosylhomocysteine hydrolase and the associated dysregulation of 1-carbon metabolism in nonalcoholic steatohepatitis and hepatocellular carcinoma.Nonalcoholic fatty liver disease and liver transplantation - Where do we stand?Longterm outcome of the liver graft: A clinician's perspective-recurrent disease, the universal shifting.Mouse models for investigating the underlying mechanisms of nonalcoholic steatohepatitis-derived hepatocellular carcinoma.Successful combination of direct antiviral agents in liver-transplanted patients with recurrent hepatitis C virus.Non-alcoholic fatty liver disease, non-alcoholic steatohepatitis, metabolic syndrome and hepatocellular carcinoma-a composite scenario.Capybara Oil Improves Hepatic Mitochondrial Dysfunction, Steatosis, and Inflammation in a Murine Model of Nonalcoholic Fatty Liver Disease.Orbital Pseudotumor as an Extrahepatic Complication of Chronic HCV Infection.Liver transplantation and alcoholic liver disease: History, controversies, and considerations.Future Pharmacotherapy for Non-alcoholic Steatohepatitis (NASH): Review of Phase 2 and 3 TrialsElimination of Hepatitis C in Liver Transplant RecipientsNonalcoholic fatty liver disease and hepatocellular carcinomaCenter-driven and Clinically Driven Variation in US Liver Transplant Maintenance Immunosuppression Therapy: A National Practice Patterns AnalysisA simple clinical calculator for assessing cardiac event risk in liver transplant candidates: The cardiovascular risk in orthotopic liver transplantation scoreHepatitis C virus related cirrhosis decreased as indication to liver transplantation since the introduction of direct-acting antivirals: A single-center studyReduced Incidence and Better Liver Disease Outcomes among Chronic HCV Infected Patients Who Consume CannabisSystems pharmacology-based exploration reveals mechanisms of anti-steatotic effects of Jiang Zhi Granule on non-alcoholic fatty liver disease
P2860
Q33717116-6190E783-0E00-4654-9AFE-E7B8A44186B9Q33840930-2AB8CE99-B18D-4A49-B70F-AEDC316C004EQ38730712-5A7A5FF6-0B89-4034-A8C4-77F2CBB71356Q39431994-A80D2767-F78A-4707-9A93-F6A405BEB6DCQ42334110-C4A67201-A9AA-43B3-BD6F-67361F1BC308Q45325816-537ABB32-097C-4C29-9A81-6CDE2CC2481FQ46626377-C72A47F1-5BF6-4AD9-9565-AE2DAAEC8376Q47095006-620D0607-E5B0-4A8B-8DF5-2F27758CE2E4Q47156332-F88A172F-C5D7-49DD-9564-A521268A1348Q47171488-3EA20761-FFCF-41A1-AE19-C3D559E13D38Q47591332-29BC5582-65C9-4459-B0A0-37E8061CB0F3Q47778507-98ABEFC3-61C2-4EF0-965C-A9731F82B511Q49199556-9C0505F7-D1B9-4D94-83FB-39EDD3F7D1B6Q49432292-3CE24D34-4CFD-4E70-B3FB-03101339A3EAQ50063376-E5489FF1-DB01-4CFE-B54F-77E489AD6DDDQ52584505-0340AD08-0027-438E-8CEA-3B918B7EB34EQ53699019-8314C67F-CE3D-4593-A556-A50506EBF239Q54212012-7441C73B-0DF1-49E0-A8EC-23B1B50F9D13Q54245484-CC450C22-276E-4FC4-B884-D77D88ACD70CQ55091847-F0E7F499-7B56-4890-A7F8-A678279D154DQ55262262-0CAF8B84-3644-40A3-B6A7-7A92767EF24FQ55553786-185A3A40-4AED-4775-A6B0-3EE9BF24AC35Q55711867-523185DC-770A-4A25-8B24-8CB3A4AD8A74Q57066927-A97C97F5-58B1-4D96-B9FA-CE06E59FDC5FQ57066937-3E1767C8-1151-4AEB-9693-D13CA0465B3DQ57095486-7D1A2E03-DB01-4508-A09D-D0DC60163160Q57179174-9CF012F1-C3BF-47A4-A244-9FFDB449D910Q57465021-4A55AED5-F0C6-4082-A0AB-DC93D09E9A8FQ57815092-8477D3C5-F9A2-4B2B-B74F-9C24BCB02A96Q57821728-A1F69E5F-4EF9-47F7-AAEF-12D3ED601B63Q58747347-AF03E014-0BA6-4BDD-A8BE-8D8392AED3A3
P2860
Changes in the Prevalence of Hepatitis C Virus Infection, Nonalcoholic Steatohepatitis, and Alcoholic Liver Disease Among Patients With Cirrhosis or Liver Failure on the Waitlist for Liver Transplantation.
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年論文
@yue
2017年論文
@zh-hant
2017年論文
@zh-hk
2017年論文
@zh-mo
2017年論文
@zh-tw
2017年论文
@wuu
2017年论文
@zh
2017年论文
@zh-cn
name
Changes in the Prevalence of H ...... ist for Liver Transplantation.
@en
type
label
Changes in the Prevalence of H ...... ist for Liver Transplantation.
@en
prefLabel
Changes in the Prevalence of H ...... ist for Liver Transplantation.
@en
P2093
P2860
P921
P1433
P1476
Changes in the Prevalence of H ...... ist for Liver Transplantation.
@en
P2093
Andrew Aronsohn
David Goldberg
Emmanuel C Gorospe
Ivo C Ditah
Kia Saeian
Michael Charlton
Mona Lalehzari
P2860
P304
1090-1099.e1
P356
10.1053/J.GASTRO.2017.01.003
P407
P577
2017-01-11T00:00:00Z